Robotic Biopsy Devices Market Size, Share & Trends Analysis Report By Product, By Application, By End-Use, By Region And Segment Forecasts 2026 – 2035

Robotic biopsy devices are advanced systems using robotics, imaging, and AI for precise, minimally invasive tissue sampling to diagnose diseases like cancer.

Key factors include rising cancer prevalence, technological advancements in robotics and AI, demand for minimally invasive procedures, and supportive healthcare policies.

The market is expected to reach USD 180 million by 2035.

The CAGR is 8.7%.

North America will contribute notably due to advanced infrastructure and high adoption rates.

Major players include Medtronic, Renishaw plc, iSYS Medizintechnik GmbH, Biobot Surgical Pte Ltd, and Intuitive Surgical Operations, Inc.

The report provides detailed insights into market size, segments, trends, key players, regional dynamics, and forecasts.

Stages include R&D and design, manufacturing of systems and accessories, regulatory approvals, distribution to healthcare facilities, clinical use, and post-market support.

Preferences are shifting toward AI-enhanced, minimally invasive devices with better accuracy, faster recovery, and outpatient suitability.

Regulatory approvals like FDA clearances drive growth by ensuring safety, while environmental factors include sustainable manufacturing and reduced procedure waste.